Intuitive Surgical, a long term healthcare play, is acknowledged as a pioneer in robotic surgery technology. A huge and growing installed base means plenty of earnings visibility from its recurring customers.

SINGAPORE (Jan 23): Nasdaq-listed Intuitive Surgical (ISRG) develops, manufactures, and markets robotic-assisted systems that help empower doctors and hospitals to make surgeries less invasive. The flagship innovation of the company is the da Vinci Surgical System launched in 1999, with multiple improved variations of this system launched ever since. Apart from da Vinci, the Ion Endoluminal System, which obtained US FDA approval earlier last year is another key innovation of the company that enables minimally invasive biopsy in the peripheral lung. Both these systems generate recurring revenue for ISRG through the sales and from operating leases. Currently, 72% of ISRG’s revenue is recurring.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply


Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook